Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyridostigmine and Insulin Secretion in Healthy Subjects
NCT03063515Phase 1Completed
- Sponsor
- University of Miami
- Start
- Apr 2017
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pyridostigmine in diabetes mellitus (DM), sponsored by University of Miami. Primary endpoint: First phase insulin response to IV glucose infusion at 10 minutes. Started Apr 2017; status: completed.
02
Drugs
pyridostigmine
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT03063515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03063515.